Keep talking, and keep on watching. Boy I wish you'd short the stock and bragg about it:))
You are so weird. My friends and I called it right and warned you about the fall before it came. You were wrong. Instead of at least listening to use you continued to be a big mouth and still not recognize the favor we did for you. You lied and tried to trick newbies in regards to your price targets of from 1200 to 6400. You were wrong in regards to Beer-gate. It will be bigger than you thought once we hear......even though you didn't want to admit, the company itself has with a recent news release to try and break the news more gently. You then try and play both sides against the middle stating that you and others....including halt-the-little-ranger left the stock to diversify and you didn't thus suffer the huge loss that you really did, but you are lying, or you lead other newbies to financial collapse with your 1200 to 6400 price target while you left like we advised you to. You are an amazing guy in your own mind. t
CGB activates ERK and AKT kinases in cancer cells via LHCGR-independent mechanism
Tumor Biology, 03/06/2014 Clinical Article
Glodek A, et al. – Expression of human chorionic gonadotropin free beta subunit (hCGβ) and its hyperglycosylated variant (hCGβ–H) is a phenomenon confirmed for tumors of different origin. Despite numerous studies, the mechanism of hCGβ action in cancer remains unknown especially that not all tumors secreting hCGβ express the receptor for human chorionic gonadotropin (LHCGR). The study also demonstrated that the presence of the receptor is a key factor influencing the magnitude of cells’ response.
Akt inhibitor MK-2206 promotes anti-tumor activity and cell death by modulation of AIF and Ezrin in colorectal cancer Full Text
BMC Cancer, 03/06/2014 Clinical Article
Agarwal E, et al. – Authors have reported that TGFβ/PKA/PP2A–mediated tumor suppressor signaling regulates Akt phosphorylation in association with the dissociation of survivin/XIAP complexes leading to inhibition of stress–dependent induction of cell survival. The identification of these 2 novel mechanisms leading to induction of cell death indicates MK–2206 might be a potential clinical candidate for therapeutic targeting of the subset of IGF1R–dependent cancers in CRC.
A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation Full Text
BMC Cancer, 03/07/2014 Clinical Article
Wiegand KC, et al. – The authors studied the influence of histological subtype on protein expression with reverse phase protein array (RPPA) and assessed proteomic changes associated with ARID1A mutation/BAF250a expression in EC and CCC. Proteomic assessment of CCC and EC demonstrates remarkable differences in protein expression that are dependent on histotype, thereby further characterizing these cancers. AKT phosphorylation is associated with ARID1A/BAF250a deficient tumors, however in ovarian cancers the mechanism remains to be elucidated.
3-Bromopyruvate induces apoptosis in breast cancer cells by downregulating Mcl-1 through the PI3K/Akt signaling pathway
Anti-Cancer Drugs, 03/07/2014 Clinical Article
Liu Z, et al. – The hexokinase inhibitor 3–bromopyruvate (3–BrPA) can inhibit glycolysis in tumor cells to reduce ATP production, resulting in apoptosis. However, as 3–BrPA is an alkylating agent, its cytotoxic action may be induced by other molecular mechanisms. These findings indicate that 3–BrPA induces apoptosis in breast cancer cells by downregulating Mcl–1 through the phosphoinositide–3–kinase/Akt signaling pathway.
An important biomarker to maybe look out for and see if it is affected by Archexin is GOLF1:
renal cell carcinoma (RCC). These results suggest that GOLPH3 expression is likely to have important roles in RCC development and progression, and that GOLPH3 is a prognostic biomarker and a promising therapeutic target for RCC.
Expression of GOLPH3 was examined in 43 fresh RCC tissues and paired adjacent normal renal tissues by real-time quantitative PCR and western blotting.
Immunohistochemistry for GOLPH3 was performed on additional 218 RCC tissues.
The clinical significance of GOLPH3 expression was analysed.
Downregulation of GOLPH3 was performed using small-interfering RNA (siRNA) in Caki-1 and 786-O cells with high abundance of GOLPH3, and the effects of GOLPH3 silencing on cell proliferation, migration, invasion in vitro, and tumour growth in vivo were evaluated.
Expression of GOLPH3 was upregulated in the majority of the RCC clinical tissue specimens at both mRNA and protein levels.
Clinicopathological analysis showed that GOLPH3 expression was significantly correlated with T stage (P
You are the lier, and tricky too. You noted the share price would go to somewhere between 1200 and 6400. With that so-called potential and your strong beliefs.....now you are saying you sold most of your shares and diversified?! And you were also wrong when you said that Mr. Beer-gate would just be a hiccup in price, and a slap on the hand from the FDA.........doesn't look that way when the company themselves release otherwise. You again show you are way off target and in your own world.......I do know that your dog thinks you are king of the universe anyway. t
Still that low IQ, unimaginative concentration on prune juice and old woman's panties. All of you ID's are looking worse and more stupid by the day. t
You need to face that maybe something that is bigger than you realize, or understand, or can conceive is transpiring and it will most likely continue as the trend is your friend unless it changes. Your comments become more entertaining as time goes on. t
Elevated liver enzymes in some patient in that little 23 patient study that went over 11 times normal. Mr. Beer before the FDA got to know the real Mr. Beer let him get away with murder. In most studies if a patient exceeded 3 times normal in regards to their liver studies would be automatically dropped from the study. The FDA allowed AEGR to hold the drug, and then re-allow patients back into the study. They also allowed patients to receive concomitant apheresis, and no placebo to be in the study. Many toxicology experts are perplexed how this could be. This was allowed because silver-tongued Mr. Beer was able to pull it off before the FDA really knew the real Mr. Beer. If the whole thing was to be redone with the discovered Mr. Beer, as to who he really is, I doubt that the FDA would have allowed this shameful, vacuous study to have stood. t
I think you will find your reliance on a 23 patient study to make those dogmatic statements to be incorrect over time. There will be much more troublesome diarrhea than you expect, there will be a much harder time following a draconian diet than you expect, there will be an increased exodus to the competitor that you don't expect, there will be an increased burden on the company secondary to Mr. Beer's mouth that you don't apparently want to acknowledge, and an increased use of the competitor that you don't want to acknowledge and that you underestimated in your review. I'll let the share price do most of my talking. Let's see what happens. I truly hope that children don't get on juxta as it will most probably be their demise, not the HoF. t
VICL up 3 CENTS today, ISIS only up $4.53 today. Gap to catch ISIS goes from 17,444 days of VICL moving up at the rate of a penny a day with ISIS held constant in price has now up to over 19,000 days. t
Out of here, used to people looking at a 360 degree view. Just see #$%$ who want to say the stock should be 120 and how come it isn't. The policeman thinks he's Billy Jack, doesn't know science while he puts everyone else in their place in their place. A useless board anyway. t
This statement from you as a dummy for a penny increase makes me think about John McEnroe when he ask the line judge if he was serious. Man, I guess I can put up with it, but at a penny a day up......how many days will it take for VICL to pass ISIS if ISIS stays the same price. That would be 49 X 365 if the market if the market traded 365 days a year. That really would be 17,444 trading days. Keep up the long slog. Kind like watching Forest Gump. t
Pancreatic adenocarcinoma: treating a systemic disease with systemic therapy
Journal of the National Cancer Institute, 03/03/2014 Clinical Article
Sohal DPS, et al. – Pancreatic adenocarcinoma, even when resectable, remains highly lethal. Although surgical outcomes have improved considerably, median overall survival after surgery and adjuvant therapy such as single–agent gemcitabine remains less than 2 years. The authors emphasize that a surgery–first approach is not resonant with the current understanding of pancreatic adenocarcinoma biology and that an upfront systemic approach for even resectable pancreatic cancer warrants testing in clinical trials.
AbbVie to present late-breaker PEARL-III study in patients with chronic hepatitis C at the 21st Conference on Retroviruses and Opportunistic Infections (49.87 -1.04)
Co The first detailed results from AbbVie's (ABBV) pivotal phase III study, PEARL-III, were presented today as part of the 21st Conference on Retroviruses and Opportunistic Infections (CROI) press conference and will also be presented as a late-breaker at the conference on March 4. PEARL-III evaluated the efficacy and safety of 12 weeks of treatment with AbbVie's investigational therapy with or without ribavirin (RBV) in non-cirrhotic, adult patients with chronic genotype 1b (GT1b) hepatitis C virus (HCV) infection who were new to treatment. The PEARL-III study met its primary and secondary endpoints. In the 419-patient study, sustained virologic response rates 12 weeks post-treatment (SVR12) of 99.5 and 99.0 percent were achieved with the AbbVie regimen with and without RBV, respectively. There were no study drug discontinuations due to adverse events.
In December 2006, Enanta (ENTA) and Abbott announced a worldwide agreement to collaborate on the discovery, development and commercialization of HCV NS3 and NS3/4A protease inhibitors and HCV protease inhibitor-containing drug combinations. ABT-450 is a protease inhibitor identified as a lead compound through the collaboration.
BTW, watch ISIS in the near future, the CEO was on Mad Money tonight. t